Ozempic for obstructive sleep apnea: Eligibility, Coverage, FDA Status 2026

Q: Is Ozempic approved for obstructive sleep apnea?

Off-label. Off-label for OSA; on-label for type 2 diabetes. Weight loss can reduce OSA severity.

The short answer

Zepbound (tirzepatide) became the first GLP-1-class drug FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024).

Ozempic specifically

Off-label for OSA; on-label for type 2 diabetes. Weight loss can reduce OSA severity.

BMI & eligibility

The Zepbound OSA indication requires obesity. Other GLP-1s remain off-label for OSA and qualify through the obesity pathway (BMI ≥30, or ≥27 with comorbidity).

Check your BMI

BMI calculator

Height (cm)Weight (kg)

Overweight27.7

BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).

BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.

Insurance & coverage

Zepbound now has a direct OSA pathway — a sleep study confirming moderate-to-severe OSA plus obesity supports prior authorization. Other GLP-1s require an obesity-based PA.

Check if your plan covers it

We earn affiliate commissions from listed providers. See our editorial standards.

Other GLP-1s for obstructive sleep apnea

GLP-1 medications for obstructive sleep apnea Wegovy for obstructive sleep apnea Zepbound for obstructive sleep apnea Mounjaro for obstructive sleep apnea

Ozempic for other conditions

Ozempic for PCOS Ozempic for prediabetes Ozempic for insulin resistance Ozempic for type 2 diabetes Ozempic for obesity Ozempic for fatty liver disease (MASH/NAFLD)

See all GLP-1 eligibility guides

Sources

Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.